HealthcareServices

Global Cancer Anorexia-Cachexia Syndrome (CACS) Market Trends and Growth Analysis 2025–2029

November 27, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

By How Much Is The Cancer Anorexia-Cachexia Syndrome (CACS) Market Expected To Expand Between 2025 And 2029?

The market for cancer anorexia-cachexia syndrome (cacs) has experienced significant expansion recently. Projections indicate its value will increase from $3.51 billion in 2024 to $3.88 billion by 2025, reflecting a compound annual growth rate (CAGR) of 10.7%. Historically, this growth can be ascribed to factors such as an escalating incidence of cancer, enhanced awareness among medical practitioners, a heightened emphasis on improving the quality of life for cancer patients, the broadening scope of clinical trials, and strategic pharmaceutical collaborations and partnerships.

The cancer anorexia-cachexia syndrome (CACS) market size is set for considerable growth over the next few years. It is projected to reach $5.79 billion in 2029, growing at a compound annual growth rate (CAGR) of 10.5%. This expansion during the forecast period can be attributed to factors like improved cancer survival rates, increasing investments in oncology supportive care, the rise of personalized medicine, a growing emphasis on multimodal therapies, and expanding healthcare infrastructure. Key developments expected during this period include advancements in palliative care, the emergence of targeted therapies, technological innovations in drug delivery systems, the integration of AI in drug development processes, and the further evolution of personalized medicine.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21125&type=smp

Which Major Market Drivers Are Shaping The Future Of The Cancer Anorexia-Cachexia Syndrome (CACS) Market?

The escalating prevalence of cancer is anticipated to propel the cancer anorexia-cachexia syndrome market’s growth moving forward. Cancer, a broad term for diseases marked by uncontrolled growth and spread of abnormal cells, is seeing a global rise in rates. This increase is driven by factors such as an aging population, lifestyle changes, environmental exposures, improved detection methods, and heightened awareness, alongside genetic predispositions and infections linked to certain cancers. Cancer anorexia-cachexia syndrome (CACS) helps address this growing cancer burden by focusing on managing the severe weight loss and malnutrition often observed in cancer patients, thereby enhancing their overall quality of life and treatment outcomes. For instance, in August 2024, a report by the UK-based charitable organization Macmillan Cancer Support indicated that over 3 million people in the UK are living with cancer, a number expected to climb to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Thus, the expanding prevalence of cancer directly drives the growth of the cancer anorexia-cachexia syndrome market.

What Are The Leading Segments Analyzed In The Cancer Anorexia-Cachexia Syndrome (CACS) Market?

The cancer anorexia-cachexia syndrome (cacs)market covered in this report is segmented –

1) By Indication: Weight Loss Prevention; Appetite Loss; Muscle Wasting; Inflammation; Other Indications

2) By Therapeutics: Progestogen; Corticosteroid; Combination Therapy; Other Therapeutics

3) By Mechanism Of Action: Appetite Stimulants; Anti-inflammatory Agents; Hormone Therapies; Cannabinoids; Other Mechanism Of Actions

4) By Route of Administration: Oral; Intravenous; Subcutaneous; Transdermal; Other Route of Administration

5) By Application: Hospitals; Clinics; Home Care

Subsegments:

1) By Weight Loss Prevention: Nutritional Supplements; Metabolic Modulators

2) By Appetite Loss: Appetite Stimulants; Ghrelin Receptor Agonists

3) By Muscle Wasting: Anabolic Agents; Selective Androgen Receptor Modulators (SARMs)

4) By Inflammation: Anti-Inflammatory Drugs; Cytokine Inhibitors

5) By Other Indications: Combination Therapies; Supportive Care Interventions

How Are Emerging Market Trends Shaping The Cancer Anorexia-Cachexia Syndrome (CACS) Industry Landscape?

Leading companies operating within the cancer anorexia-cachexia syndrome market are concentrating on creating novel solutions, including monoclonal antibody therapies, to boost treatment effectiveness, better patient results, and fulfill outstanding clinical requirements. These monoclonal antibody therapies utilize laboratory-produced antibodies crafted to target specific antigens on cancerous cells, thus assisting the immune system in identifying and combating them more efficiently. For instance, in September 2024, Pfizer Inc., a US-based pharmaceutical and biotechnology corporation, disclosed favorable outcomes from its Phase II clinical trial for ponsegromab, a monoclonal antibody specifically targeting Growth/Differentiation Factor 15 (GDF-15). The encouraging data from this research provides promise for an alternative treatment path for individuals suffering from this severe condition, given the current scarcity of effective treatments. The findings from the Phase 2 trial indicate substantial advancement in tackling the fundamental inflammatory mechanisms that lead to muscle wastage and weight reduction in cancer patients. This therapeutic strategy seeks not only to improve physical capabilities but also to uplift the general quality of life for those with cancer, representing a crucial development in oncology care.

Which Major Firms Are Strengthening Their Position In The Cancer Anorexia-Cachexia Syndrome (CACS) Industry?

Major companies operating in the cancer anorexia-cachexia syndrome (CACS) market are Pfizer Inc., Merck & Co. Inc., Ono Pharmaceutical Co. Ltd., Mundipharma International Limited, Yuhan Corporation, Helsinn Healthcare SA, AVEO Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Larix Bioscience LLC, Aeterna Zentaris Inc., Artelo Biosciences Inc., Sapphire Therapeutics Inc., Endevica Bio, AAVogen Inc., Actimed Therapeutics Ltd., Aphios Corporation, Betula Pharmaceuticals AB, Cannabics Pharmaceuticals Inc., Creative Medical Technology Holdings Inc., Abreos Biosciences Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/cancer-anorexia-cachexia-syndrome-cacs-global-market-report

Which Regional Markets Are Contributing Most To The Cancer Anorexia-Cachexia Syndrome (CACS) Industry Expansion?

North America was the largest region in the cancer anorexia-cachexia (CACS) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer anorexia-cachexia syndrome (CACS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Cancer Anorexia-Cachexia Syndrome (CACS) Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21125&type=smp

Browse Through More Reports Similar to the Global Cancer Anorexia-Cachexia Syndrome (CACS) Market 2025, By The Business Research Company

Cancer Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Bladder Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/bladder-cancer-drugs-global-market-report

Blood Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795